Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Free Cash Flow (2016 - 2025)

Standard Biotools (LAB) has disclosed Free Cash Flow for 16 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 133.17% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$75.2 million through Dec 2025, up 50.47% year-over-year, with the annual reading at -$75.2 million for FY2025, 50.47% up from the prior year.
  • Free Cash Flow for Q4 2025 was $5.8 million at Standard Biotools, up from -$29.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was $5.8 million in Q4 2025, with the low at -$63.3 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$23.6 million, with a median of -$19.9 million recorded in 2021.
  • The sharpest move saw Free Cash Flow crashed 3887.2% in 2022, then soared 133.17% in 2025.
  • Over 5 years, Free Cash Flow stood at -$500000.0 in 2021, then plummeted by 3887.2% to -$19.9 million in 2022, then surged by 43.28% to -$11.3 million in 2023, then crashed by 54.24% to -$17.4 million in 2024, then skyrocketed by 133.17% to $5.8 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $5.8 million, -$29.8 million, and -$15.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.